0.5783  0.024 (4.39%)		11-02 15:19
Open: 0.589 High: 0.6622 Volume: 362,221		Pre. Close: 0.554 Low: 0.5783 Market Cap: 54(M)

Short term
Mid term
Targets	6-month :	1.03	1-year :	1.31
Resists	First :	0.89	Second :	1.12
Pivot price	0.66
Supports	First :	0.5	Second :	0.41
MAs	MA(5) :	0.58	MA(20) :	0.7
	MA(100) :	0.75	MA(250) :	0.9
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	19.7	D(3) :	13.7
RSI	RSI(14): 41.1
52-week	High :	1.83	Low :	0.49

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CTOR ] has closed above bottom band by 43.2%. Bollinger Bands are 27.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.57 - 0.57	0.57 - 0.57
Low:	0.5 - 0.5	0.5 - 0.5
Close:	0.55 - 0.55	0.55 - 0.56

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.

Fri, 30 Oct 2026
Citius Oncology, Inc. (CTOR) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Fri, 30 Oct 2026
Citius Oncology, Inc. (CTOR) Seasonal returns chart - Yahoo Finance UK

Wed, 28 Oct 2026
Citius Oncology (Nasdaq:CTOR) - Stock Analysis - Simply Wall St

Mon, 26 Oct 2026
With its sales team nationwide, Citius Oncology (CTOR) reports preliminary, unaudited shipment growth. - Stock Titan

Mon, 26 Oct 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 - PR Newswire

Fri, 23 Oct 2026
Nasdaq gives Citius Oncology (NASDAQ: CTOR) more time to meet its $1 share-price rule. - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	106 (M)
Shares Float	31 (M)
Held by Insiders	77.5 (%)
Held by Institutions	15.2 (%)
Shares Short	290 (K)
Shares Short P.Month	469 (K)

EPS	-0.48
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.37
Profit Margin	0 %
Operating Margin	-595.6 %
Return on Assets (ttm)	-29.2 %
Return on Equity (ttm)	-126.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.05
Sales Per Share	0.06
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-19 (M)
Levered Free Cash Flow	-31 (M)

PE Ratio	-1.34
PEG Ratio	0
Price to Book value	1.68
Price to Sales	9.53
Price to Cash Flow	-3.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.